Download PDF

Register to download the report. Already a member?

 
 
Sign Up

Or

62462 1502285060HCLSReviewMexicoJuly2017.pdf
Energy Boardroom

OncoGenex sinks, sees prostate potential after custirsen failure

29.04.2014 / Scripintelligence

Bothell, Washington-based OncoGenex closed at $3.85 per share on 28 April versus $9.70 before the weekend. The company shed $86.1m of its value, bringing its market cap to $56.7m based on the first set of Phase III data for its lead drug candidate….

LATEST ISSUE

DOWNLOAD

X
Download PDF

First Name:

Last Name:

Company:

Position:

Country:

Email: